Table 1.
Baseline characteristics of study participants.
| Characteristics | Overall N = 310 |
I-TLD N = 171 |
T-TLD N = 139 |
|---|---|---|---|
| Female | 162 | 87 | 75 |
| Male | 148 | 84 | 64 |
| Median age in years | 41 (34–49) | 39 (32–48) | 42 (36–49) |
| Region of residence: | |||
| Yaoundé | 209 | 128 | 81 |
| Douala | 101 | 43 | 58 |
| WHO clinical stage (n = 178) *: | |||
| I | 120 | 84 | 36 |
| II | 28 | 21 | 07 |
| III | 18 | 11 | 07 |
| IV | 12 | 07 | 05 |
| Median ART-duration on first-line [IQR] (months) | 19 (13–27) |
14 (12–17) |
28 (24.5–31) |
| Median ART-duration on TLD [IQR] (months) | 14 (11–15) |
14 (12–17) |
14 (9–15) |
| Median viremia before transition [IQR] (copies/mL) | 3258 (831–59,276) |
/ | 3258 (831–59,276) |
Legend: I-TLD refers to participants initiated on ART with TLD; T-TLD refers to participants transitioned from TLE to TLD; IQR refers to interquartile range. * Data regarding the WHO clinical stages at treatment initiation was available only for 178 participants.